Poolbeg PharmaPOLBF 3-Year ROIIC % is -1,676.38 as of Dec. 2025. The stock has 1 warning sign investors should review. Among 1,325 Biotechnology companies, Poolbeg Pharma ranks worse than 96.23% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Poolbeg Pharma's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -1,676.38%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Poolbeg Pharma's 3-Year ROIIC % or its related term are showing as below:
POLBF's 3-Year ROIIC % is ranked worse than 96.23% of 1325
companies
in the Biotechnology industry
Industry Median: -4.44
vs POLBF: -1676.38
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Poolbeg Pharma 3-Year ROIIC % Related Terms
Poolbeg Pharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Poolbeg Pharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
POLBF vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Poolbeg Pharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Poolbeg Pharma 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Poolbeg Pharma's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Poolbeg Pharma (POLBF) has a 3-Year ROIIC % of -1,676.38 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Poolbeg Pharma and its competitors. According to the industry distribution chart, Poolbeg Pharma ranks #1275 out of 1325 companies in the Biotechnology industry, placing it in the top 96.2%.
Is Poolbeg Pharma's 3-Year ROIIC % too high?
Poolbeg Pharma's current 3-Year ROIIC % is -1,676.38. Based on the distribution chart, Poolbeg Pharma ranks #1275 out of 1325 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Poolbeg Pharma's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Poolbeg Pharma ranks #1275 out of 1325 companies for 3-Year ROIIC %. This places Poolbeg Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Poolbeg Pharma and its competitors. Poolbeg Pharma's current 3-Year ROIIC % is -1,676.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current 3-Year ROIIC % of -1,676.38. The current 3-Year ROIIC % is -1,676.38. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current 3-Year ROIIC % is -1,676.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
POLBF has been successfully added to your 